ERBB2 and breast cancer: Besides, exosomes released from HER2-overexpressing BC cells containing the HER2 protein neutralized the HER2-targeted antibody-based drug trastuzumab and attenuated its interaction with the intended BC target cells, leading to enhanced aggressiveness (Ciravolo et al., 2012).